Neuropore Therapies, Inc., a clinical stage biopharmaceutical company announced today that it has been awarded a $500,000 grant from The ALS Association to support the preclinical evaluation and development of its leading Toll-Like Receptor 2 (TLR2) antagonist NPT1220-312 for the treatment of amyotrophic lateral sclerosis. The grant has been made through the Association’s Lawrence and Isabel Barnett Drug Development Program.
Neuropore Therapies, Inc., a clinical stage biopharmaceutical company announced today that it has successfully completed the Phase 1 clinical trial in healthy volunteers with NPT520-34. NPT520-34 is a small molecule being developed for Parkinson’s disease and amyotrophic lateral sclerosis.
Neuropore Therapies, Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the underlying causes of neurodegenerative disease, announced today the appointment of Joseph S. McCracken, DVM, MS to its board of directors.
Neuropore Therapies, Inc. announced today that it has received orphan drug designation for NPT520-34 for the treatment of amyotrophic lateral sclerosis or ALS. The orphan drug designation will facilitate the development of NPT520-34 in the treatment of this debilitating medical condition for which limited treatments are available.
Neuropore Therapies, Inc. announced today that it entered into a collaboration with BenevolentAI to evaluate molecular targets implicated in progressive degenerative diseases which were identified through artificial intelligence. The molecular targets of interest are implicated in dysfunctions in proteostasis and can therefore be modulated to restore normal cellular protein clearance mechanisms. The collaboration aims to discover small molecule therapeutics for multiple targets.
Neuropore Therapies, Inc. announced today that partner UCB initiated a multicenter clinical trial in Parkinson’s disease patients with UCB0599 in the United States of America. UCB0599, an alpha-synuclein misfolding inhibitor, is a therapeutic candidate arising from the Neuropore-UCB collaboration. Neuropore will receive a $5 million (USD) award as a result of achieving this milestone.Neuropore Initiates Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson’s Disease and Amyotrophic Lateral Sclerosis May 8, 2019
Neuropore Therapies, Inc. announced today that it has initiated a Phase 1 clinical trial in healthy volunteers with NPT520-34. This Phase 1 study is designed to evaluate the safety, tolerability and pharmacokinetics of NPT520-34.Neuropore Therapies Awarded Second Grant on its TLR2 Program from The Michael J. Fox Foundation for Parkinson’s Research January 4, 2018
Neuropore Therapies, Inc. has received a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.Neuropore Therapies Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research January 30, 2017
Neuropore Therapies, Inc. has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.Neuropore Therapies Announces Appointment of Dr. Errol De Souza as President and Chief Executive Officer January 23, 2017
Neuropore Therapies, Inc. announced today that Errol De Souza, Ph.D. has been appointed President and Chief Executive Officer effective immediately.Neuropore Therapies (NPT) Announces Achievement of Key Program Milestone September 13, 2016
Based on promising findings from ongoing clinical and non-clinical studies, UCB awarded NPT a major program milestone of $5 million.Neuropore publishes paper describing use of retinal imaging for evaluating potential therapies for Parkinson’s disease and other synucleinopathies August 4, 2016
The report in Scientific Reports describes findings that support the use of non-invasive retinal imaging in animal models as a tool to monitor the fate of α-synuclein accumulation in the CNS and to evaluate the effects of putative therapeutic agents targeting α-synuclein for Parkinson’s disease and other synucleinopathiesNeuropore Announces Successful Completion of Phase l with its Lead Compound NPT200-11 March 7, 2016
NPT200-11 was well tolerated in 55 volunteers after oral administrationNeuropore Therapies Commences Phase 1 Clinical Trials August 12, 2015
Neuropore Therapies Inc. commences Phase 1 clinical trials with NPT200-11; a potential new disease modifying treatment for Parkinson's DiseaseNeuropore And UCB Enter Into World-Wide Collaboration And Agreement January 15, 2015
Companies collaborate in the development of a small molecule disease modifying treatment option for people living with Parkinson's diseaseCompletion Of A Study On Retinal Pathology In An Animal Model Of Parkinson's Disease April 8, 2014
Neuropore Therapies Inc. and collaborators at the University of California, San Diego complete a study on the progression of Parkinson's disease in Laboratory Animals Using Phoenix Research Labs' Retinal Imaging Technology.Advancement Of NPT200-11 Into Preclinical Development January 30, 2014
NeuroPore Therapies, a San Diego based biopharmaceutical company dedicated to the discovery and development of novel therapeutics for neurodegenerative disorders, with support from the Michael J. Fox foundation, has initiated preclinical development of its lead compound for the treatment of Parkinson’s disease.